View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 12, 2020

Stabilitech signs a manufacturing deal with BioCell for its oral Covid-19 vaccine

By Allie Nawrat

UK-based Stabilitech has signed a manufacturing deal with New Zealand-based BioCell for its oral, investigational Covid-19 vaccine, OraPro-COVID-19

Stabilitech chairman Wayne Channon explained: “After a successful recent fundraising round, this signed agreement represents a crucial next step for OraPro-COVID-19.

“It brings us closer to providing a vaccine that gives both mucosal and systemic immunity to Covid-19.

This will target the virus exactly where we catch it: in the mucous membranes of the mouth, nose, throat and even the eyes.

By taking this approach, we believe OraPro-COVID-19 could prove to provide the fastest route to widespread global immunity, turning the tide on the pandemic.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology